EquitiesAmerica.com
Educational content — not investment advice

Insulet Corporation

PODDNMSHealthcare
Visit Website

Data as of April 18, 2026

Key Metrics

Market Cap

$14.34B

P/E Ratio

58.38

P/B Ratio

9.46

Dividend Yield

Return on Equity

0.18%

Debt / Equity

66.18

Insider Ownership

0.31%

Institutional Own.

105.44%

Employees

5,400

Sector & Industry

Sector

Healthcare

Industry

Medical Devices

About Insulet Corporation

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Ownership Snapshot

Insider0.31%
Institutional105.44%
Public / Other0.00%

Source: Yahoo Finance / SEC filings. For full details, see the Holdings page.

Explore More

Disclaimer: All data on this page is historical and sourced from publicly available databases including SEC EDGAR and Yahoo Finance. EquitiesAmerica.com is an educational publisher and does not provide personalized investment guidance, securities analysis, or trading recommendations. Past data does not predict future results. Please consult a registered investment professional before making any financial decision. Read full disclaimer.